$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000156459022012683 Filed on March 30, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.718M	$20.45M	$2.500M
YoY Change	48.72%	37.7%	-56.97%
% of Gross Profit
Research & Development	$7.912M	$22.90M	$3.280M
YoY Change	141.22%	56.95%	-42.25%
% of Gross Profit
Depreciation & Amortization	$28.00K	$114.0K	$20.00K
YoY Change	40.0%	67.65%	0.0%
% of Gross Profit
Operating Expenses	$11.63M	$22.90M	$5.790M
YoY Change	100.86%	-31.55%	-49.61%
Operating Profit		-$66.02M
YoY Change		97.33%
Interest Expense	-$460.0K	-$1.249M	-$320.0K
YoY Change	43.75%	11.52%	113.33%
% of Operating Profit
Other Income/Expense, Net		-$709.0K
YoY Change		-36.81%
Pretax Income	-$12.09M	-$66.73M	-$6.130M
YoY Change	97.23%	92.98%	-47.29%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$12.09M	-$66.73M	-$6.130M
YoY Change	97.23%	92.98%	-47.29%
Net Earnings / Revenue
Basic Earnings Per Share		-$38.15
Diluted Earnings Per Share	-$139.7K	-$953.7K	-$152.7K
COMMON SHARES
Basic Shares Outstanding		1.749M
Diluted Shares Outstanding		1.749M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.27M	$42.27M	$24.67M
YoY Change	71.33%	71.33%	-56.16%
Cash & Equivalents	$42.27M	$42.27M	$24.67M
Short-Term Investments
Other Short-Term Assets	$1.212M	$1.212M	$1.230M
YoY Change	-1.46%	-1.46%	-13.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$43.48M	$43.48M	$25.89M
YoY Change	67.92%	67.94%	-55.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$216.0K	$1.659M	$133.0K
YoY Change	62.41%	201.64%	-33.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$30.00K
YoY Change	-100.0%	-100.0%	-73.45%
Total Long-Term Assets	$1.659M	$1.659M	$584.0K
YoY Change	184.08%	181.19%	-52.83%
TOTAL ASSETS
Total Short-Term Assets	$43.48M	$43.48M	$25.89M
Total Long-Term Assets	$1.659M	$1.659M	$584.0K
Total Assets	$45.14M	$45.14M	$26.48M
YoY Change	70.48%	70.46%	-55.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.379M	$1.379M	$481.0K
YoY Change	186.69%	187.29%	-74.29%
Accrued Expenses	$4.196M	$4.853M	$2.924M
YoY Change	43.5%	60.7%	-37.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$5.239M
YoY Change	-100.0%	-100.0%	20.83%
Total Short-Term Liabilities	$9.955M	$9.955M	$9.838M
YoY Change	1.19%	1.17%	-16.68%
LONG-TERM LIABILITIES
Long-Term Debt	$12.00M	$12.00M	$6.376M
YoY Change	88.14%	88.03%	-39.29%
Other Long-Term Liabilities	$804.0K	$804.0K	$30.00K
YoY Change	2580.0%	2580.0%	-93.02%
Total Long-Term Liabilities	$12.00M	$12.80M	$6.376M
YoY Change	88.14%	99.69%	-39.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.955M	$9.955M	$9.838M
Total Long-Term Liabilities	$12.00M	$12.80M	$6.376M
Total Liabilities	$22.76M	$22.76M	$16.25M
YoY Change	40.06%	40.03%	-28.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$238.3M		-$171.6M
YoY Change	38.88%		25.24%
Common Stock	$262.9M		$183.7M
YoY Change	43.15%		4.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.38M	$22.38M	$10.23M
YoY Change
Total Liabilities & Shareholders Equity	$45.14M	$45.14M	$26.48M
YoY Change	70.48%	70.46%	-55.08%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$12.09M	-$66.73M	-$6.130M
YoY Change	97.23%	92.98%	-47.29%
Depreciation, Depletion And Amortization	$28.00K	$114.0K	$20.00K
YoY Change	40.0%	67.65%	0.0%
Cash From Operating Activities	-$9.931M	-$35.00M	-$4.670M
YoY Change	112.66%	24.27%	-49.57%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$89.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.145M	$0.00
YoY Change		-93.65%	-100.0%
Cash From Investing Activities	-$20.00K	$2.056M	$0.00
YoY Change		-93.92%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-160.0K	50.79M	-1.250M
YoY Change	-87.2%	-1577.25%	-340.38%
NET CHANGE
Cash From Operating Activities	-9.931M	-35.00M	-4.670M
Cash From Investing Activities	-20.00K	2.056M	0.000
Cash From Financing Activities	-160.0K	50.79M	-1.250M
Net Change In Cash	-10.11M	17.84M	-5.920M
YoY Change	70.79%	715.49%	-1841.18%
FREE CASH FLOW
Cash From Operating Activities	-$9.931M	-$35.00M	-$4.670M
Capital Expenditures	-$20.00K	$89.00K
Free Cash Flow	-$9.911M	-$35.09M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q1	elox	Restructuring And Related Costs Severance Cost Payment Period RestructuringAndRelatedCostsSeveranceCostPaymentPeriod	P1Y
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P2Y8M26D
CY2021	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P1Y8M26D
CY2021	elox	Class Of Warrant Or Right Exercisable Expiration Period ClassOfWarrantOrRightExercisableExpirationPeriod	P1Y8M26D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M23D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y9M14D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.76
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.72
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.76
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0087
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0036
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0151
CY2021	elox	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsContractualTerm	P10Y
CY2020	elox	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsContractualTerm	P10Y
CY2019	elox	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsContractualTerm	P10Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.77
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	1.33
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0163
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0262
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42268000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24668000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	299000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	56000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	913000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1169000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	43480000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	25893000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	216000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1443000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	421000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000
CY2020Q4	us-gaap	Assets Assets	26477000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	481000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2924000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9838000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6376000
CY2020Q4	us-gaap	Liabilities Liabilities	16247000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	404000
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1828000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	183250000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	22899000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14590000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	26349000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	22670000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	22670000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9167000
CY2021	us-gaap	Profit Loss ProfitLoss	-66727000
CY2020	us-gaap	Profit Loss ProfitLoss	-34577000
CY2019	us-gaap	Profit Loss ProfitLoss	-50874000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-18000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	169000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	421000
CY2019	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-395000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11336000
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	18000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-50874000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	36213000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71000
CY2020	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-125000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8666000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-18000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-34577000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	10230000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	22335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-66727000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22384000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8666000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	11336000
CY2021	us-gaap	Depreciation Depreciation	114000
CY2020	us-gaap	Depreciation Depreciation	68000
CY2019	us-gaap	Depreciation Depreciation	87000
CY2021	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	846000
CY2020	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	503000
CY2019	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	472000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	420000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	563000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	535000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-15000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	301000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-84000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000
CY2021	elox	Gain On Extinguishment Of Paycheck Protection Program Debt GainOnExtinguishmentOfPaycheckProtectionProgramDebt	808000
CY2021	elox	Loss On Extinguishment Of Term Debt LossOnExtinguishmentOfTermDebt	268000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-582000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-262000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-83000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-320000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1390000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1124000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	535000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1774000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1379000
CY2021	us-gaap	Payments For Merger Related Costs PaymentsForMergerRelatedCosts	1003000
CY2021	elox	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-829000
CY2020	elox	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-502000
CY2019	elox	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-472000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35001000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28166000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39391000
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2145000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	67214000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33750000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33750000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000
CY2020	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	-42000
CY2019	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	22000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2056000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33792000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33524000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11874000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	797000
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	276000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	11383000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4583000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	71000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	169000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	710000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	362000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	125000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1378000
CY2021	elox	Proceeds From Advances From Collaboration Partners ProceedsFromAdvancesFromCollaborationPartners	2918000
CY2020	elox	Proceeds From Advances From Collaboration Partners ProceedsFromAdvancesFromCollaborationPartners	402000
CY2019	elox	Proceeds From Advances From Collaboration Partners ProceedsFromAdvancesFromCollaborationPartners	403000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50788000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3438000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46800000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17843000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2188000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26115000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24724000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22536000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48651000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42567000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24724000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22536000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42268000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24668000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22493000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	299000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	56000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	43000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	728000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	828000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	986000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	36000
CY2019	elox	Non Cash Issuance Of Shares Upon Exercise Of Warrants NonCashIssuanceOfSharesUponExerciseOfWarrants	179000
CY2019	elox	Fair Value Of Warrants Issued In Connection With Long Term Debt FairValueOfWarrantsIssuedInConnectionWithLongTermDebt	421000
CY2019	elox	Remeasurement Of Operating Leases RemeasurementOfOperatingLeases	176000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238300000
CY2021Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	42300000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	38000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2924000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	77000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.58%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates estimates on an ongoing basis in light of changes in circumstances, facts and experiences. Actual results could materially differ from those estimates. </p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42300000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24700000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	170000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	377000
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	368000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	913000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1169000
CY2021Q4	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	413000
CY2020Q4	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	631000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	123000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	387000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	446000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	171000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	313000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	216000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133000
CY2021	us-gaap	Depreciation Depreciation	114000
CY2020	us-gaap	Depreciation Depreciation	68000
CY2019	us-gaap	Depreciation Depreciation	87000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86649958
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	258000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	415000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	77000
CY2021Q4	elox	Accrued Interest On Debt AccruedInterestOnDebt	102000
CY2020Q4	elox	Accrued Interest On Debt AccruedInterestOnDebt	57000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4196000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2924000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	600000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M17D
CY2021	elox	Operating Lease Weighted Average Incremental Borrowing Rate OperatingLeaseWeightedAverageIncrementalBorrowingRate	0.080
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	715000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	704000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	125000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1546000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	85000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1461000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	657000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	804000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4204000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6101000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2195000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	12500000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1323000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	11177000
CY2021Q4	elox	Long Term Debt Maturities Final Fee Due LongTermDebtMaturitiesFinalFeeDue	-819000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11996000
CY2021	elox	Clinical And Regulatory Milestone Payments Received ClinicalAndRegulatoryMilestonePaymentsReceived	3600000
CY2021	us-gaap	Payments For Royalties PaymentsForRoyalties	0
CY2021Q1	elox	Additional Payments Received From Collaboration Partners AdditionalPaymentsReceivedFromCollaborationPartners	2600000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	323892
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.31
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	323892
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.31
CY2021Q4	elox	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	323892
CY2021Q4	elox	Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice	4.31
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3803061
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.16
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1936183
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6503412
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.38
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23491
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.05
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1378538
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.44
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8904444
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.24
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	254223
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2851186
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.40
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	254223
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7800000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.29
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.28
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9167000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8666000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11336000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-47849000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18582000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-22242000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66727000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34577000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50874000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57716000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43759000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3143000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2200000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	337000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	431000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6009000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3624000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3988000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2511000
CY2021Q4	elox	Deferred Tax Assets Operating Lease Right Of Use Assets DeferredTaxAssetsOperatingLeaseRightOfUseAssets	338000
CY2020Q4	elox	Deferred Tax Assets Operating Lease Right Of Use Assets DeferredTaxAssetsOperatingLeaseRightOfUseAssets	98000
CY2021Q4	elox	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	363000
CY2020Q4	elox	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	98000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	371000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	59000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71589000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	52584000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71589000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52584000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71600000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52600000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19000000.0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5900000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.009
CY2021	elox	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.073
CY2020	elox	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.020
CY2019	elox	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.035
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.029
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.188
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.238
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5900000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3600000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	700000
CY2021	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The Company is subject to income taxes in the United States and Israel and Australia. The Company files income tax returns in the U.S. and in several states. The federal and state tax returns are generally subject to tax examination by taxing authorities for tax years December 31, 2018 to present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Israeli income tax returns remain open to examination beginning in 2013 to present. The Australia income tax returns remain open to examination beginning in 2021 to present. If and when the Company claims NOL carryforwards from any prior years against future taxable income, those losses may be examined by the taxing authorities.
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-66727000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-34577000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-50874000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69962843
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40124953
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38063173
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.86
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4476678
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5525509
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9234599
CY2020	us-gaap	Interest And Other Income InterestAndOtherIncome	337000
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	8000
CY2019	us-gaap	Interest And Other Income InterestAndOtherIncome	1072000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-35000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-76000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	-15000
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	301000
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	1259000
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	1409000
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	1616000
CY2021	elox	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	808000
CY2021	elox	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	268000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-709000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1122000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-319000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	elox	Number Of Geographic Regions NumberOfGeographicRegions	3
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42268000
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	42268000
CY2021Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost	42268000
CY2021Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	42268000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24668000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	24668000
CY2020Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost	24668000
CY2020Q4	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	24668000
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2020Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	13
CY2020Q1	us-gaap	Severance Costs1 SeveranceCosts1	4000000.0
CY2020Q1	elox	Restructuring And Related Cost Stock Based Compensation Expense RestructuringAndRelatedCostStockBasedCompensationExpense	2100000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	1894000
CY2020	us-gaap	Payments For Restructuring PaymentsForRestructuring	1636000
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	258000

Files In Submission

Name	View Source	Status
0001564590-22-012683-index-headers.html	Edgar Link	pending
0001564590-22-012683-index.html	Edgar Link	pending
0001564590-22-012683.txt	Edgar Link	pending
0001564590-22-012683-xbrl.zip	Edgar Link	pending
elox-10k_20211231.htm	Edgar Link	pending
elox-10k_20211231_htm.xml	Edgar Link	completed
elox-20211231.xsd	Edgar Link	pending
elox-20211231_cal.xml	Edgar Link	unprocessable
elox-20211231_def.xml	Edgar Link	unprocessable
elox-20211231_lab.xml	Edgar Link	unprocessable
elox-20211231_pre.xml	Edgar Link	unprocessable
elox-ex211_9.htm	Edgar Link	pending
elox-ex231_6.htm	Edgar Link	pending
elox-ex311_10.htm	Edgar Link	pending
elox-ex312_7.htm	Edgar Link	pending
elox-ex321_8.htm	Edgar Link	pending
elox-ex322_11.htm	Edgar Link	pending
elox-ex42_60.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gi0mlacjp3cr000001.jpg	Edgar Link	pending
gi0mlacjp3cr000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2021 Q4 Form 10-K Financial Statement

#000156459022012683 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2021 Q4 Form 10-K Financial Statement

#000156459022012683 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox